Management of Chronic Obstructive Pulmonary Disease (COPD)

Introduction to COPD Management

COPD management involves a comprehensive approach, including pharmacological and non-pharmacological interventions, to improve symptoms, quality of life, and reduce exacerbations, as recommended by the American Thoracic Society and the Global Initiative for Chronic Obstructive Lung Disease 1, 2

For patients with forced expiratory volume in one second (FEV1) <60% predicted, combination therapy with long-acting inhaled medications is recommended, as per the American College of Physicians 3
The American College of Physicians recommends that adding a long-acting muscarinic antagonist (LAMA) to existing therapy can reduce exacerbation rates and improve lung function in patients with COPD, 3
Combination therapy with long-acting inhaled medications can reduce exacerbation rates and improve quality of life measures, 3
Patients with FEV1 less than 60% predicted may be considered for combination therapy, particularly those with a history of exacerbations (≥2 exacerbations per year) or asthma-COPD overlap syndrome (ACOS) 3, 4
The European Respiratory Society recommends ICS/LABA combinations for patients with frequent exacerbations despite optimal bronchodilation, FEV1 <50-60% predicted, and history of ACOS 4

LAMA/LABA combination therapy is recommended for patients with persistent symptoms to prevent exacerbations, according to the American Thoracic Society 1
Triple therapy, including LAMA/LABA and inhaled corticosteroids (ICS), is recommended for patients who develop additional exacerbations on LAMA/LABA therapy, especially those with moderate-to-very severe COPD and high exacerbation risk, as stated by the American Thoracic Society and the Global Initiative for Chronic Obstructive Lung Disease 1
LAMAs are recommended over LABAs as first-line therapy to prevent exacerbations and improve outcomes in patients with moderate to severe COPD, with a Grade 1C recommendation, according to the American Thoracic Society 2
ICS should be considered for patients with blood eosinophil counts ≥300 cells/μL, with a strength of evidence rated as high, as suggested by the American Thoracic Society 2, 5, 6
Roflumilast is indicated for patients with severe COPD with chronic bronchitis and a history of exacerbations, but should be considered only after optimizing bronchodilator therapy, including triple therapy with LAMA/LABA/ICS, according to the European Respiratory Society 4

Smoking cessation is essential at all stages of disease and is the most effective intervention to slow disease progression, as recommended by Thorax 7
Pulmonary rehabilitation should be considered for patients with moderate symptom burden (mMRC score of 2) to improve overall management of COPD, as recommended by the Canadian Thoracic Society 6
Long-term oxygen therapy (LTOT) is recommended for patients with resting hypoxemia (PaO2 <7.3 kPa) and reduces mortality in hypoxemic patients, as recommended by Thorax and Annals of Internal Medicine 7, 8

mMRC Score	Symptom Burden	Recommended Treatment
0-1	Mild	SABA as needed
2	Moderate	LABA + SABA as needed + pulmonary rehabilitation
≥3	Severe	LAMA/LABA combination therapy, consider ICS for patients with elevated eosinophils

Patient education should ensure proper inhaler technique for all devices and emphasize the importance of adherence to the full regimen, with consideration given to single-inhaler triple therapy options to improve adherence 2

The American College of Physicians notes that there is an increased risk of pneumonia with the inhaled corticosteroid (ICS) component, 3
ICS use in COPD patients is associated with an increased risk of pneumonia, particularly in those with certain underlying conditions, and should be monitored 4, 1
Systemic corticosteroids are not recommended for long-term management of stable COPD due to significant adverse effects, according to the American College of Allergy, Asthma, and Immunology and the British Thoracic Society 9, 7
Oral corticosteroids should be reserved for acute exacerbations, typically given as short courses (e.g., 30mg daily for 7-14 days) 7